DRUG DISCOVERY TECHNOLOGIES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Drug Discovery Technologies in Millions of US$. The specific technology types analyzed are Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics, and Other Drug Discovery Technologies (Include Combinatorial Chemistry, Nanotechnology and RNAi). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 187 companies including many key and niche players such as -

Abbott Laboratories
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research, Inc.
Amersham Biosciences
Applera Corporation


Click here to request a full list of companies covered in the report...

Code: MCP-1506
Price: $3950
Companies: 187
Pages: 675
Date: October 2008
Market Data Tables: 163

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Bioanalytical Instruments.....I-4
Nuclear Magnetic Resonance.....I-4
Mass Spectroscopy.....I-4
Microplate Readers.....I-4
Chemotherapy Instruments.....I-4
High Throughput Screening (HTS).....I-4
Genomics.....I-4
Proteomics.....I-4
  
   Bioinformatics.....I-5
Biochip.....I-5
Pharmacogenomics.....I-5
Other Drug Discovery Technologies.....I-5
  
   Drug Discovery Outsourcing – A Necessity.....II-1
Current & Future Analysis.....II-1
Analysis by Geographic Region.....II-1
1$100
   Analysis by Technology Type.....II-2
1$100
   Bioinformatics.....II-3
Pharmacogenomics.....II-3
1$100
   Theragnostics.....II-41$100
   Targeted Therapy.....II-5
Mass Spectrometry – A New Catalyst for Technological Developments.....II-5
3$300
   New Technologies Fire Up Drug Discovery Market.....II-8
Obesity Related Diseases Driving Drug Discovery Research.....II-8
Biochips Change Face of Drug Discovery.....II-8
Genomics and Proteomics Gaining Prominence.....II-8
1$100
   Genomics Drives Bioinformatics Growth in Drug Discovery.....II-9
Market Scenario of Human Genome Sciences (HGS).....II-9
International Initiatives Expand Proteomics.....II-9
1$100
   Drug Discovery – Definition.....II-10
Drug Discovery Process.....II-10
1$100
   Drug Discovery Technologies.....II-11
Bioanalytical Instruments.....II-11
Nuclear Magnetic Resonance.....II-11
Mass Spectroscopy.....II-11
Microplate Readers.....II-11
1$100
   Chemotherapy Instruments.....II-12
High Throughput Screening.....II-12
Genomics.....II-12
Functional Genomics.....II-12
Structural Genomics.....II-12
Proteomics.....II-12
1$100
   Classification of Proteomics.....II-13
Bioinformatics.....II-13
Categories of Bioinformatics.....II-13
Advantages of Bioinformatics in Drug Discovery.....II-13
Market Highlights.....II-13
1$100
   Biochip.....II-14
Types of Biochips.....II-14
Pharmacogenomics.....II-14
1$100
   A Revolutionary Health Care Therapy.....II-151$100
   Other Drug Discovery Technologies.....II-16
Combinatorial Chemistry.....II-16
Lab-on-a-Chip.....II-16
1$100
   RNA Interference.....II-17
1$100
   Affymetrix Introduces Cytogenetic Solution.....II-18
Affymetrix Introduces DMET Early Access Solution.....II-18
Affymetrix Microarray Platform to feature in Pathwork’s Diagnostic Test.....II-18
Bio-Rad Laboratories Rolls Out Vasculitis Kit for BioPlex 2200 System.....II-18
1$100
   PerkinElmer Develops Products for High-Throughput Screening.....II-19
Tecan to Introduce Multimode Microplate Reader- Infinite M1000.....II-19
Waters Introduces Next-Generation MS System - Synapt™.....II-19
Tripos International Launches SYBYL®8.0.....II-19
1$100
   Bio-Rad Laboratories Unveils In2it A1C Analyzer for Diabetic Patients.....II-20
Charles River Launches Endosafe®-MCS™ Endotoxin Detection System.....II-20
Invitrogen Launches Human Embryonic Stem Cells Monitoring Kit.....II-20
1$100
   Sigma-Aldrich Introduces Proteomics Dynamic Range Standard.....II-21
Molecular Devices Develops Arcturus (XT) ™ LMC Instrument.....II-21
Fujitsu’s BioSciences Renames CAChe Software and Releases Scigress Explorer™.....II-21
Tripos International Unveils Topomer CoMFA®.....II-21
Tripos International Launches Topomer Search.....II-21
1$100
   Sigma-Aldrich Introduces GenomePlex®.....II-22
Agilent Unveils Dual Mode Microarray Platform.....II-22
Molecular Devices Launches ImageXpressULTRA™.....II-22
Applied Biosystems Commercializes TaqMan® Influenza.....II-22
Agilent Launches Assay Kits for Lab-On-a-Chip Platform.....II-22
1$100
   Affymetrix Unveils GeneChip® Microarrays.....II-23
Quantum Introduces Drug Discovery Software.....II-23
Invitrogen Launches Stealth™ RNAi Human Kinase Collection.....II-23
PerkinElmer Unveils BioXPRESSION™.....II-23
Affymetrix and ParAllele Jointly Introduce MegAllele™ Assays.....II-23
Agilent Launches HD-CGH Custom Microarrays.....II-23
1$100
   Applied Biosystems and MDS Sciex Unveil Tempo™ LC.....II-24
Beckman Coulter Presents Chemistry Analyzer for Clinical Testing.....II-24
Molecular Devices Launches ADME Assay Kits.....II-24
Applied Biosystems Unveils LS*LIMS™ Software.....II-24
Affymetrix Presents NimbleExpress™.....II-24
Agilent Releases Software for Pharma QC/QA.....II-24
1$100
   Affymetrix Acquires USB Corp.....II-25
Roche Acquires Ventana Medical Systems.....II-25
Bruker BioSciences Acquires Bruker BioSpin Group.....II-25
Takeda Signs Agreement to Take Over Millennium.....II-25
1$100
   Pfizer to Acquire Serenex.....II-26
Implant Sciences to Acquire Ion Metrics.....II-26
1$100
   NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs.....II-27
DiscoveRx and Cosmo Bio Sign Distribution Agreement.....II-27
1$100
   Zydus Cadila Enters into Collaboration with Prolong Pharmaceuticals.....II-28
PsychoGenics Enters into Drug Discovery Agreement with Dainippon.....II-28
Zydus Cadila Collaborates with Karo Bio.....II-28
1$100
   Nicholas Piramal’s R&D Unit Extends Alliance with Eli Lilly.....II-29
Dr. Reddy’s Signs Collaboration Agreement with 7TM Pharma.....II-29
1$100
   Synamatix Enters into Collaboration with Universiti Malaysia.....II-30
Monogram Enters into Exclusive Collaboration Agreement with Avexa.....II-30
1$100
   Caliper Life Sciences Collaborates with Horizon Discovery.....II-31
Galapagos Signs Collaborative Agreement with Allergan for Drug Discovery.....II-31
Sigma-Aldrich Inks Exclusive Distribution Partnership with Atlas Antibodies.....II-31
1$100
   PsychoGenics Enters into New Agreement with Eli Lilly.....II-32
Ambrx and Eli Lilly Enter into Alliance for Drug Discovery.....II-32
BioSeek Enters into Agreement with Dainippon Sumitomo.....II-32
1$100
   NicOx Extends Collaboration with Pfizer.....II-33
BioFocus DPI Extends Contract with Lilly.....II-33
Invitrogen to Collaborate with Tecan.....II-33
1$100
   Ranbaxy Forms New Drug Discovery Company.....II-34
Protagen to Expand Protein Biochips Business.....II-34
Znomics Expands Facilities for Drug Discovery.....II-34
1$100
   Eli Lilly Acquires ICOS Corporation.....II-35
CMC Announces Acquisition of ICOS Biologics Facility from Eli Lilly.....II-35
SurModics Acquires Brookwood.....II-35
1$100
   Commonwealth Biotechnologies Acquires Tripos Discovery Research.....II-36
VASTox Acquires Dextra Laboratories and Daniolabs.....II-36
1$100
   Takeda Completes Acquisition of Paradigm.....II-37
Wyeth Completes the Acquisition of Haptogen.....II-37
1$100
   Roche Takes Over Nimblegen.....II-38
AMRI Acquires Pharmaceutical Manufacturing Units in India.....II-38
1$100
   Morvus Acquires Cardiff Biologicals and ProTides.....II-39
Agilent Technologies Acquires Stratagene.....II-39
1$100
   AstraZeneca Takes Over MedImmune.....II-40
Ocimum Acquires Gene Logic's Genomics Business.....II-40
Newsham Genetics Acquires Monsanto Choice Genetics.....II-40
Evotec Takes Over Combinature Biopharm’s Drug Discovery Unit.....II-40
1$100
   BioServe Takes Over Genomics Collaborative.....II-41
Thomson Takes Over Unleashed Informatics Ltd.....II-41
Thomson Completes Acquisition of Prous Science.....II-41
1$100
   MDS Acquires Molecular Devices.....II-42
Evotec to Take over Renovis.....II-42
Ecopia Merges with Caprion.....II-42
1$100
   Domainex Merges with NCE Discovery.....II-43
Thallion Sells Majority Interest in Caprion Proteomics Business.....II-43
Affymetrix Enters into Licensing Agreement with Empire Genomics.....II-43
1$100
   Graffinity Pharmaceuticals Signs Drug Discovery Agreement with Amgen.....II-44
ArQule Signs License Deal with Kyowa Hakko.....II-44
Toshiba, Canon and Others to Join Forces to Develop Biochips.....II-44
Orion and ChemDiv Enter into Collaborative Deal.....II-44
1$100
   Graffinity Enters into Drug Discovery Collaboration with Pfizer.....II-45
Tata Enterprise Establishes Pharmaceutical Development Centre.....II-45
Nicholas Piramal Collaborates with Merck.....II-45
1$100
   Eksigent Signs Distribution Agreement with Interface Engineering.....II-46
LEAD Therapeutics Enters Collaboration with Shang Pharma.....II-46
MDS Pharma Expands Chinese Lab Operations.....II-46
1$100
   Ambit Extends Drug Discovery Collaboration with Bristol - Myers Squibb.....II-47
PsychoGenics Enters into Agreement with Cephalon for Drug Discovery.....II-47
Abbott and Caprion Proteomics Extends Partnership.....II-47
1$100
   Agilent Technologies and BioNanomatrix Enters into Collaboration.....II-48
Evotec Extends Partnership with Boehringer Ingelheim.....II-48
Evotec and Interprotein Enter into Collaboration.....II-48
Galapagos Forms Drug Innovation Alliance with AstraZeneca.....II-48
1$100
   Proteome Systems and BD Enter into an Agreement.....II-49
Galapagos Extends Drug Innovation Partnership with Amgen.....II-49
1$100
   Dimerix Collaborates with NCDS.....II-50
ACE BioSciences and CLC Bio Enter into Collaborative Agreement.....II-50
1$100
   Ambrx Enters into Strategic Agreement with Merck & Co.....II-51
Galapagos and Cystic Fibrosis Collaborate for Drug Discovery.....II-51
1$100
   BioDiscovery Collaborates with Illumina.....II-52
Advinus Collaborates with DNDi.....II-52
1$100
   Jubilant & Forest Enter into Partnership Deal.....II-53
Cisbio to Employ Lumi4™ Technology of Lumiphore.....II-53
Invitrogen Corporation Signs Agreement with Emiliem to Screen Kinase
  Inhibitors.....II-53
1$100
   AMRI Establishes New Center in India.....II-54
Actavis Takes Over Abrika.....II-54
Galapagos Announces Acquisition of Inpharmatica.....II-54
PerkinElmer Acquires Proteomics Technology from Agilix.....II-54
1$100
   BD Finishes Acquisition of GeneOhm.....II-55
Albany Acquires ComGenex in Hungary.....II-55
Agilent Acquires Yokogawa.....II-55
1$100
   Strand Forms Partnership with Microsoft BioIT Alliance.....II-56
Nicholas Piramal Signs License Agreement with Morvus Technology.....II-56
Cellomics and Evotec Sign a Patent License Agreement.....II-56
PerkinElmer Opens New Technology Center in Shanghai.....II-56
1$100
   Affymetrix Acquires ParAllele.....II-57
Agilent Acquires Computational Biology.....II-57
MultiCell and Living Cell Enter into a Joint Venture.....II-57
1$100
   Fujitsu and Ensemble Enter into Licensing Agreement.....II-58
Structural GenomiX Modifies Licensing Agreement with Lilly.....II-58
Provid Enters into Research Services Agreement with Palatin.....II-58
NascaCell Signs Co-marketing Agreement with DPI.....II-58
Evotec and P&G Sign Supply Agreement.....II-58
Invitrogen Signs Collaborative Agreement with NCDS.....II-58
1$100
   HistoRx Enters into Collaboration with Eli Lilly.....II-59
Invitrogen and Applied Biosystems Forge Strategic Alliance.....II-59
UCB and ChemBridge Form Collaboration in Discovery Chemistry.....II-59
Pharmacopeia and CV Therapeutics Form Drug Discovery and Development
  Collaboration.....II-59
1$100
   OriGene Enters into Collaboration with Cytomyx.....II-60
Discovery Partners Divests Discovery Systems Business to Nexus.....II-60
CRL Acquires River Valley Farms.....II-60
Agilent Acquires Silicon.....II-60
Medarex Acquires Ability Biomedical.....II-60
1$100
   National Instruments Enters into Joint Venture Agreement with Agilent.....II-61
Amersham Enters into 3-Year Distribution Agreement with Guava.....II-61
ChemBridge Signs an Agreement with Merck & Co......II-61
Bristol-Myers Collaborates with MEDX.....II-61
Bayer Enters into Partnership with Physiomics.....II-61
Pharmacopeia Spins-Off Pharmacopeia Drug Discovery.....II-61
1$100
   Abbott Enters into Collaboration with Caprion.....II-62
Vertex Divests Instrumentation Assets to Aurora.....II-62
1$100
   Abbott Laboratories (US).....II-63
Affymetrix Inc. (US).....II-63
Agilent Technologies Inc. (US).....II-63
Albany Molecular Research, Inc. (US).....II-63
1$100
   Amersham Biosciences (US).....II-64
Applera Corporation (US).....II-64
ArQule Inc. (US).....II-64
AstraZeneca (UK).....II-64
1$100
   BD Biosciences (US).....II-65
Bio-Rad Laboratories, Inc. (US).....II-65
BioSciences Group (Japan).....II-65
Caliper Life Sciences, Inc. (US).....II-65
1$100
   Capital GenomiX (US).....II-66
Caprion Proteomics (Canada).....II-66
Charles River Laboratories International, Inc. (US).....II-66
ChemBridge Corporation (US).....II-66
deCODE Genetics, Inc (Iceland).....II-66
1$100
   Evotec AG (Germany).....II-67
Galapagos NV (Belgium).....II-67
Incyte Corporation (Formerly Incyte Genomics Inc.) (US).....II-67
Infinity Pharmaceuticals, Inc. (US).....II-67
Invitrogen Corporation (US).....II-67
1$100
   Medarex, Inc. (US).....II-68
Merck & Co., Inc. (US).....II-68
Millennium Pharmaceuticals, Inc. (US).....II-68
National Center for Drug Screening (China).....II-68
PerkinElmer, Inc. (US).....II-68
Pharmacopeia Inc. (US).....II-68
1$100
   Proteome Systems (Australia).....II-69
Quantum Pharmaceuticals (Russia).....II-69
Shimadzu Corporation (Japan).....II-69
Sigma-Aldrich (US).....II-69
Tecan Group (Switzerland).....II-69
1$100
   Thallion Pharmaceuticals, Inc. (Canada).....II-70
Tripos International (US).....II-70
1$100
   Table 1: World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-711$300
   Table 2: World Long-term Projections for Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-721$300
   Table 3: World 10-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-731$300
   Analytics by Drug Discovery Technology Type.....II-74
Table 4: World Recent Past, Current & Future Analysis for Bioanalytical Instruments by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-74
1$300
   Table 5: World Long-term Projections for Bioanalytical Instruments by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-751$300
   Table 6: World 10-Year Perspective for Bioanalytical Instruments by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-761$300
   Table 7: World Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-771$300
   Table 8: World Long-term Projections for High Throughput Screening (HTS) by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-781$300
   Table 9: World 10-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-791$300
   Table 10: World Recent Past, Current & Future Analysis for Biochip by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-801$300
   Table 11: World Long-term Projections for Biochip by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-811$300
   Table 12: World 10-Year Perspective for Biochip by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-821$300
   Table 13: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-831$300
   Table 14: World Long-term Projections for Proteomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-841$300
   Table 15: World 10-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-851$300
   Table 16: World Recent Past, Current & Future Analysis for Genomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-861$300
   Table 17: World Long-term Projections for Genomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-871$300
   Table 18: World 10-Year Perspective for Genomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-881$300
   Table 19: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-891$300
   Table 20: World Long-term Projections for Bioinformatics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-901$300
   Table 21: World 10-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-911$300
   Table 22: World Recent Past, Current & Future Analysis for Pharmacogenomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-921$300
   Table 23: World Long-term Projections for Pharmacogenomics by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-931$300
   Table 24: World 10-Year Perspective for Pharmacogenomics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-941$300
   Table 25: World Recent Past, Current & Future Analysis for Other Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....II-951$300
   Table 26: World Long-term Projections for Other Drug Discovery Technologies by Geographic Region – US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-961$300
   Table 27: World 10-Year Perspective for Other Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-971$300
   A. Market Analysis.....III-1
Overview.....III-1
US Leads the World High Throughput Screening (HTS) Market.....III-1
1$75
   Current & Future Analysis.....III-2
Product Launches.....III-2
7$525
   Strategic Corporate Developments.....III-919$875
   Focus on Select US Players.....III-28
Abbott Laboratories.....III-28
Affymetrix Inc......III-28
Agilent Technologies Inc......III-28
Albany Molecular Research, Inc......III-28
1$75
   Amersham Biosciences.....III-29
Applera Corporation.....III-29
ArQule Inc......III-29
1$75
   BD Biosciences.....III-30
Bio-Rad Laboratories, Inc......III-30
Caliper Life Sciences, Inc......III-30
Capital GenomiX.....III-30
1$75
   Charles River Laboratories International, Inc......III-31
ChemBridge Corporation.....III-31
deCODE Genetics, Inc......III-31
HistoRx, Inc......III-31
Incyte Corporation (Formerly Incyte Genomics Inc.).....III-31
1$75
   Infinity Pharmaceuticals, Inc......III-32
Invitrogen Corporation.....III-32
Medarex, Inc......III-32
Merck & Co., Inc......III-32
Millennium Pharmaceuticals, Inc......III-32
PerkinElmer, Inc......III-32
1$75
   Pharmacopeia Inc......III-33
Provid Pharmaceuticals, Inc......III-33
Tigris Pharmaceuticals, Inc......III-33
Sigma-Aldrich.....III-33
Tripos International.....III-33
1$75
   B. Market Analytics.....III-34
Table 28: US Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-34
1$150
   Table 29: US Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-351$150
   Table 30: US 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-36
1$150
   A. Market Analysis.....III-37
Current & Future Analysis.....III-37
Strategic Corporate Developments.....III-37
1$75
   Focus on Select Canadian Players.....III-38
Caprion Proteomics.....III-38
Thallion Pharmaceuticals, Inc......III-38
1$75
   B. Market Analytics.....III-39
Table 31: Canadian Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-39
1$150
   Table 32: Canadian Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-401$150
   Table 33: Canadian 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-41
1$150
   A. Market Analysis.....III-42
Current & Future Analysis.....III-42
Japan Resembles US in Life Science Research.....III-42
Strategic Corporate Developments.....III-42
1$75
   Focus on Select Japanese Players.....III-43
BioSciences Group.....III-43
Shimadzu Corporation.....III-43
1$75
   B. Market Analytics.....III-44
Table 34: Japanese Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-44
1$150
   Table 35: Japanese Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-451$150
   Table 36: Japanese 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-46
1$150
   A. Market Analysis.....III-47
Current & Future Analysis.....III-47
An Overview of Pharmacogenomics and Personalized Medicine.....III-47
1$75
   Emerging Trends in Proteomics Technology.....III-48
Protein Classification.....III-48
1$75
   Protein Separation.....III-491$75
   Market Trends.....III-50
European Market for Drug Discovery Tools.....III-50
UK Government Supports Proteomics Research.....III-50
Drug Discovery Outsourcing in Europe.....III-50
1$75
   Recent Industry Activity.....III-519$675
   Focus on Select European Players.....III-60
AstraZeneca (UK).....III-60
deCODE Genetics, Inc (Iceland).....III-60
Evotec AG (Germany).....III-60
NascaCell IP GmbH (Germany).....III-60
1$75
   Quantum Pharmaceuticals (Russia).....III-61
Tecan Group (Switzerland).....III-61
UCB (Belgium).....III-61
1$75
   B. Market Analytics.....III-62
Table 37: European Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-62
1$150
   Table 38: European Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-631$150
   Table 39: European 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-64
1$150
   A. Market Analysis.....III-65
Current & Future Analysis.....III-65
Asia-Pacific.....III-65
Emerging Opportunities.....III-65
Cost Advantage in Asia Attracts Global Drug Discovery Industry.....III-65
Regulations Affect Asia-Pacific Drug Discovery Market.....III-65
1$75
   India.....III-66
Bioinformatics Market in India.....III-66
Scope and Demand for Bioinformatics Market to Expand Significantly by
  2010.....III-66
1$75
   Discovery of Therapeutic Molecules – A New Buzzword for Growth
  Acceleration.....III-67
1$75
   Strategic Corporate Developments.....III-687$525
   Focus on Select Players.....III-75
National Center for Drug Screening (China).....III-75
Proteome Systems (Australia).....III-75
1$75
   B. Market Analytics.....III-76
Table 40: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics & Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart).....III-76
1$150
   Table 41: Rest of World Long-term Projections for Drug Discovery Technologies by Technology Type – Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-771$150
   Table 42: Rest of World 10-Year Perspective for Drug Discovery Technologies by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-781$150
  
Total Companies Profiled: 187 (including Divisions/Subsidiaries - 199)

Region/Country Players

The United States 128 Canada 2 Japan 9 Europe 39 France 3 Germany 9 The United Kingdom 10 Rest of Europe 17 Asia-Pacific (Excluding Japan) 21
Click here to request a full table of contents and more details on this project.